Skip to main content
SpringerLink
Log in

Personalized Models of Human PDAC

  • Chapter
  • First Online:
Translational Pancreatic Cancer Research

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 373 Accesses

Abstract

Pancreatic cancer is one of the most aggressive malignancies with large inter- and intratumoural heterogeneity and an extremely poor prognosis. Uniform treatments adapted to disease states, but ignoring the individual cancer biology, are still the standard of care. Yet, response to therapy varies substantially among pancreatic cancer patients, and most antitumour therapies can cause serious side effects. Thus, selection of the optimal therapy for each individual patient is of central importance for combating this devastating disease. Unfortunately no biomarkers that reliably predict treatment effects in individual PDAC patients are currently available. This limitation could be overcome by functional testing of live patient-derived tumour models. Several personalized models of human PDAC have been developed, including patient-derived xenografts, cell lines, 3D organoids, tumour tissue slice and circulating tumour cell cultures. Those models enable drug screenings and could help to select the optimal therapy for individual patients, improving survival and reducing toxic side effects by obviating inefficient medications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.

    PubMed  Google Scholar 

  2. Strobel O, Neoptolemos J, Jager D, Buchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11–26.

    Article  CAS  PubMed  Google Scholar 

  3. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.

    Article  CAS  PubMed  Google Scholar 

  4. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15(12):747–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, et al. Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer. Cell Rep. 2016;16(7):2017–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling pancreatic cancer with organoids. Trends Cancer. 2016;2(4):176–90.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Delitto D, Pham K, Vlada AC, Sarosi GA, Thomas RM, Behrns KE, et al. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol. 2015;185(5):1297–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mattie M, Christensen A, Chang MS, Yeh W, Said S, Shostak Y, et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia. 2013;15(10):1138–50.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wege AK. Humanized mouse models for the preclinical assessment of cancer immunotherapy. BioDrugs. 2018;32(3):245–66.

    Article  CAS  PubMed  Google Scholar 

  16. Wiekmeijer AS, Pike-Overzet K, Brugman MH, Salvatori DC, Egeler RM, Bredius RG, et al. Sustained engraftment of cryopreserved human bone marrow CD34(+) cells in young adult NSG mice. Biores Open Access. 2014;3(3):110–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011;17(17):5793–800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Reyes G, Villanueva A, Garcia C, Sancho FJ, Piulats J, Lluis F, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res. 1996;56(24):5713–9.

    CAS  PubMed  Google Scholar 

  19. Pergolini I, Morales-Oyarvide V, Mino-Kenudson M, Honselmann KC, Rosenbaum MW, Nahar S, et al. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. PLoS One. 2017;12(8):e0182855.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015;15(5):311–6.

    Article  CAS  PubMed  Google Scholar 

  21. Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1–2):324–38.

    Article  CAS  PubMed  Google Scholar 

  22. Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, et al. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut. 2018;67(3):508–20.

    Article  CAS  PubMed  Google Scholar 

  23. Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018;18(1):335.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005;15(5):378–86.

    Article  CAS  PubMed  Google Scholar 

  25. Tiriac H, Belleau P, Engle DD, Plenker D, Deschenes A, Somerville TDD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tiriac H, Bucobo JC, Tzimas D, Grewel S, Lacomb JF, Rowehl LM, et al. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment. Gastrointest Endosc. 2018;87(6):1474–80.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015;21(11):1364–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lim CY, Chang JH, Lee WS, Lee KM, Yoon YC, Kim J, et al. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response. Pancreatology. 2018;18(8):913–27.

    Article  CAS  PubMed  Google Scholar 

  30. Jiang X, Seo YD, Chang JH, Coveler A, Nigjeh EN, Pan S, et al. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Oncoimmunology. 2017;6(7):e1333210.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Pantel K, Alix-Panabieres C. Functional studies on viable circulating tumor cells. Clin Chem. 2016;62(2):328–34.

    Article  CAS  PubMed  Google Scholar 

  32. Sandlin RD, Wong KHK, Tessier SN, Swei A, Bookstaver LD, Ahearn BE, et al. Ultra-fast vitrification of patient-derived circulating tumor cell lines. PLoS One. 2018;13(2):e0192734.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014;9(3):694–710.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kulemann B, Pitman MB, Liss AS, Valsangkar N, Fernandez-Del Castillo C, Lillemoe KD, et al. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas. 2015;44(4):547–50.

    Article  CAS  PubMed  Google Scholar 

  35. Warkiani ME, Khoo BL, Wu L, Tay AK, Bhagat AA, Han J, et al. Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics. Nat Protoc. 2016;11(1):134–48.

    Article  CAS  PubMed  Google Scholar 

  36. Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, et al. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016;10(3):481–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. DiPardo BJ, Winograd P, Court CM, Tomlinson JS. Pancreatic cancer circulating tumor cells: applications for personalized oncology. Expert Rev Mol Diagn. 2018;18(9):809–20.

    Article  CAS  PubMed  Google Scholar 

  38. Sheng W, Ogunwobi OO, Chen T, Zhang J, George TJ, Liu C, et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip. 2014;14(1):89–98.

    Article  CAS  PubMed  Google Scholar 

  39. Kulemann B, Liss AS, Warshaw AL, Seifert S, Bronsert P, Glatz T, et al. KRAS mutations in pancreatic circulating tumor cells: a pilot study. Tumour Biol. 2016;37(6):7547–54.

    Article  CAS  PubMed  Google Scholar 

  40. Al-Lamki RS, Bradley JR, Pober JS. Human organ culture: updating the approach to bridge the gap from in vitro to in vivo in inflammation, cancer, and stem cell biology. Front Med (Lausanne). 2017;4:148.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany

    Hanna Heikenwälder & Susanne Roth

Authors
  1. Hanna Heikenwälder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Roth .

Editor information

Editors and Affiliations

  1. Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Christoph W. Michalski

  2. Department of Internal Medicine I, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Jonas Rosendahl

  3. Department of Internal Medicine I, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Patrick Michl

  4. Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany

    Jörg Kleeff

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Heikenwälder, H., Roth, S. (2020). Personalized Models of Human PDAC. In: Michalski, C., Rosendahl, J., Michl, P., Kleeff, J. (eds) Translational Pancreatic Cancer Research. Molecular and Translational Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-49476-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49476-6_10

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-49475-9

  • Online ISBN: 978-3-030-49476-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation